Pluristem (PSTI -1.3%) says Cha Bio & Diostech (the company's South Korean PAD partner) has...

|About: Pluristem Therapeutics, Inc. (PSTI)|By:, SA News Editor

Pluristem (PSTI -1.3%) says Cha Bio & Diostech (the company's South Korean PAD partner) has filed an IND with Korean regulators for the use of PLX-PAD to treat intermittent claudication. The company says it is very pleased with "the pace at which [its] new partner is moving forward towards clinical trials." PSTI announced the partnership late last month. SA contributor Sharon di Stefano believes the partnership "positions PSTI to be a cell therapy leader."